A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.

医学 培美曲塞 卡铂 内科学 多西紫杉醇 肿瘤科 贝伐单抗 队列 肺癌 化疗 彭布罗利珠单抗 临床终点 癌症 外科 顺铂 临床试验 免疫疗法
作者
Yuangyuan Zhao,Wenfeng Fang,Yunpeng Yang,Jianhua Chen,Li Zhuang,Yingying Du,Qitao Yu,Yanqiu Zhao,Wu Zhuang,Ming Zhou,Weidong Zhang,Yu Zhang,Yixin Wan,Ziping Wang,Lin Wang,Yu Xia,Baiyong Li,Sheng Wang,Weifeng Song,Li Zhang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 9019-9019 被引量:17
标识
DOI:10.1200/jco.2022.40.16_suppl.9019
摘要

9019 Background: Based on IMPOWER 150, atezolizumab in combination with bevacizumab and platinum-based chemotherapy has been the first-line treatment for advanced non-squamous NSCLC with negative driver genes. AK112 is a global first-in-class anti-PD-1/VEGF bi-specific antibody developed by Akesobio. Preclinical and clinical studies have indicated that AK112 possess potential anti-tumor efficacy in solid tumors. Therefore, we aimed to assess the efficacy and safety of AK112 in combination with chemotherapy for patients with advanced NSCLC. Methods: This was an open-label, multi-center phase II study evaluating the efficacy and safety of AK112 in combination with chemotherapy in pts with advanced NSCLC. Enrolled pts were divided into three cohorts: Previously untreated advanced NSCLC pts with wide-type EGFR/ALK (Cohort 1), pts with EGFR mutations who had failed prior EGFR-TKI therapies without T790M mutation or failed osimertinib treatment (Cohort 2), and pts who progressed after anti-PD-1/L1 and platinum-based chemotherapy (Cohort 3). Pts were treated with 10mg/kg or 20mg/kg AK112 once every 3 weeks in combination with carboplatin and pemetrexed or carboplatin and paclitaxel for Cohort 1/2, and docetaxel for Cohort 3. Primary endpoint was ORR as assessed by investigator per RECIST v1.1. Results: 133 pts were enrolled from Feb 03, 2021 to Dec 31, 2021 and received AK112 plus chemotherapy (44 received AK112 10 mg/kg and 89 received AK112 20 mg/kg). As of Dec 31, 2021, in cohort-1, among 26 evaluable pts with squamous cell carcinoma, 20 partial response and 6 stable disease were observed for a 76.9% ORR and a 100.0% DCR, median DOR and median PFS was not reached while 6-month PFS rate was 86.2%. In Cohort-2, among 19 evaluable pts, 13 partial response and 5 stable disease were observed for a 68.4% ORR and a 94.7% DCR while median DOR was 5.5 months, and median PFS was 8.3 months. In Cohort-3, among 20 evaluable pts, 8 partial response and 8 stable disease were observed for a 40.0% ORR and a 80.0% DCR, median DOR and median PFS was not reached while 6-month PFS rate was 71.1%. Treatment emergent adverse events (TEAE) occurred in 86.5% (115/133) of the pts, and grade ≥3 AEs occurred in 28.6% (38/133) of pts including two deaths. Most common AE (incidence ≥ 5%) included alanine/aspartate aminotransferase increased, epistaxis, anemia, vomiting, nausea, rash, leukopenia, thrombocytopenia, and neutropenia. Treatment discontinuation due to AE occurred in 3.0% (4/133) of the pts. Conclusions: AK112 plus chemotherapy has shown a promising anti-tumor efficacy in each cohort and warrants potentially superior safety in comparison to anti-PD-(L)1 and anti-VEGF combination therapies in advanced NSCLC. PFS and ORR were also significantly improved with AK112 plus chemotherapy. Therefore, phase III registration studies of AK112 plus chemotherapy in advanced NSCLC will be initiated in 2022. Clinical trial information: NCT04736823.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cdercder的应助被f1mike110采纳,获得10
刚刚
杨茜然发布了新的文献求助10
1秒前
Dreamer.发布了新的文献求助10
1秒前
霸气的契发布了新的文献求助10
1秒前
2秒前
2秒前
Steplan完成签到,获得积分10
2秒前
3秒前
4秒前
杨茜然发布了新的文献求助20
4秒前
4秒前
4秒前
香蕉觅云的应助被如意幼枫采纳,获得10
5秒前
6秒前
科研通AI6.3的应助被匆匆采纳,获得10
6秒前
nuodei完成签到,获得积分10
6秒前
7秒前
wish0913发布了新的文献求助10
7秒前
杨茜然发布了新的文献求助10
7秒前
7秒前
7秒前
pp1015发布了新的文献求助10
8秒前
9秒前
9秒前
zhunYY完成签到,获得积分10
10秒前
LDX完成签到,获得积分20
10秒前
霸气的契完成签到,获得积分10
10秒前
10秒前
Ludens完成签到,获得积分10
11秒前
katha发布了新的文献求助10
11秒前
小鱼发布了新的文献求助10
11秒前
Shelly完成签到,获得积分10
11秒前
动听衬衫发布了新的文献求助10
11秒前
东风的应助被结实的半双采纳,获得30
12秒前
12秒前
ZYM发布了新的文献求助10
14秒前
cch发布了新的文献求助10
14秒前
14秒前
daidai完成签到,获得积分10
16秒前
华仔的应助被调皮友安采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194041
求助须知:如何正确求助?哪些是违规求助? 9579979
关于积分的说明 21868799
捐赠科研通 7793641
什么是DOI,文献DOI怎么找? 3437477
关于科研通互助平台的介绍 2560942
邀请新用户注册赠送积分活动 2484251